

1 **Relationship between birth weight and chronic kidney**
2 **disease: an integrative analysis of observational studies and**
3 **causal inference through genetic approaches**

4

5 **Xinghao Yu^{1#}, Zhongshang Yuan^{2#}, Haimiao Chen¹, Jiaji Yang¹, Yixin Gao¹,**
6 **Fengjun Guan³, Ping Zeng^{1*}, Shuiping Huang^{1*}**

7

8 *¹ Department of Epidemiology and Biostatistics, School of Public Health, Xuzhou*
9 *Medical University, Xuzhou, Jiangsu, 221004, China*

10 *² Department of Biostatistics, School of Public Health, Shandong University, Jinan,*
11 *Shandong, 250012, China*

12 *³ Department of Pediatrics, Affiliated Hospital of Xuzhou Medical University, Xuzhou,*
13 *Jiangsu 221004, China*

14

15 [#]The authors wish it to be known that, in their opinion, the first two authors should be
16 regarded as joint first authors.

17

18 Correspondence to

19 zpstat@xzhmu.edu.cn

20 Ping Zeng

21 hsp@xzhmu.edu.cn

22 Shuiping Huang

23

24 **ABSTRACT**

25 **Objective:** Although many observational studies have shown that there was an
26 inverse association between birth weight and chronic kidney disease (CKD) in adults,
27 whether such association is causal remains largely unclear.

28 **Methods:** We first conducted a systematic review and meta-analysis to investigate the
29 association between birth weight and CKD. Then using a set of valid instrumental
30 variables for birth weight, we performed a two-sample Mendelian randomization (MR)
31 to evaluate its causal effect on CKD based on summary association statistics available
32 from large scale genome-wide association study (GWAS) (up to 143,677 individuals
33 for birth weight and 118,147 individuals for CKD). We further validated the MR
34 results with extensive sensitive analyses.

35 **Results:** The results of meta-analysis showed that individuals with low birth weight
36 have about 76% (95% CI 36~126%) higher risk of CKD in late life compared with
37 those with normal birth weight. Depending on 26 instrumental variables, the inverse
38 variance weighted MR showed that the odds ratio per one SD increase of birth weight
39 on CKD was estimated to be 0.91 (95% CI 0.72~1.14, $p=0.396$). The similar null
40 association between birth weight and CKD is also observed using the weighted
41 median method and maximum likelihood method as well as the Egger regression.
42 Such non-significant association is robust against potential instrumental outliers and
43 pleiotropic effects.

44 **Conclusion:** Our study identifies an inverse association between birth weight and
45 adult CKD in observational studies, while it is not supportive of the causal role of
46 birth weight on CKD based on our MR analysis.

47 **Keywords:** Birth weight; Chronic kidney disease; Mendelian randomization;
48 Causal association; Genome wide association study

49 **1. Introduction**

50 Chronic kidney disease (CKD) is a common complex disease which influences both
51 children and adult populations (Levey et al., 2015; Webster et al., 2017). At the initial
52 disease stage, CKD is asymptomatic and may be ignored by sufferers. It is common
53 that the diagnosis of CKD is made when disease symptoms already become severe.
54 Moreover, a series of severe complications (e.g. renal failure, hypertension, cancer,
55 infection and coronary heart disease) can occur with the decreased renal function of
56 CKD patients (Di Lullo et al., 2015; Webster et al., 2017). Additionally, due to the
57 decreased GFR during the disease progression as well as possible complications, the
58 life quality of CKD patients is significantly lower than that of the general population.

59 It is estimated that the global prevalence of CKD ranges between 11% and 13%, and
60 that CKD can account for 1.5% death worldwide, making it among the leading death
61 risk and a global public health issue (Hill et al., 2016). World Health Organization
62 (WHO) predicts that the deaths attributable to kidney-related diseases will increase by
63 31% (from ~871,000 in 2015 to ~1,143,000 in 2030) in the next decade due to the
64 growing disease rate and aging population (Organization, 2018). Therefore,
65 identifying the risk factors of CKD can promote our understanding of the
66 pathogenesis of this disease, having the potential to ultimately lead to better
67 prevention and treatment for CKD, and is also important in terms of the public health
68 perspective (Luyckx and Brenner, 2015; Luyckx et al., 2017; Webster et al., 2017).

69 CKD has complicated etiologies and both genetic and non-genetic (e.g. lifestyle and
70 environmental) risk factors to play an important role in the development of CKD (Jha
71 et al., 2013; Webster et al., 2017; Iwagami et al., 2018; Wang et al., 2018). Some
72 non-genetic risk factors (e.g. diabetes, hypertension, dyslipidemia and
73 glomerulonephritis) were previously discovered in observational studies. Additionally,
74 multiple genes (e.g. *NAT8*, *SLC7A9*, *UMOD*, *SHROOM3*, *GATM* and *MYH9*) were
75 also identified to be associated with CKD and kidney-related traits (Chambers et al.,
76 2010; Köttgen et al., 2010; Pattaro et al., 2016). More recently, several
77 epidemiological studies have shown that CKD may originate from the life of the fetus
78 — a generalized hypothesis referred to as the fetal origins hypothesis first proposed
79 by the British epidemiologist David Barker in 1990 (thus also known as Barker

80 hypothesis) (Barker, 1990; Luyckx and Brenner, 2015). The fetal origins hypothesis
81 supposes that the risk for chronic non-communicable diseases (e.g. CKD and
82 cardiovascular diseases) in later life can be partly attributed to the altered
83 developmental programming and the long-term adverse adaptations to early
84 undernutrition, both of which can lead to the structural and functional changes in
85 multiple developing tissues and organs (Zeng et al., 2019b; Zeng and Zhou, 2019a). In
86 the literature, birth weight is a widely used measurement for intrauterine environment;
87 and low birth weight often serves as an indicator of impaired renal development in
88 utero when investigating the influence of early growth on kidney-related outcomes.
89 Although most previous studies (White et al., 2009; Luyckx and Brenner, 2015; Das
90 et al., 2016), along with some animal experimental models (Barnett et al., 2017),
91 illustrated that low birth weight was associated with an increased risk of CKD; owing
92 to the heterogeneity in disease onset age, geographic diversity and ethnic differences,
93 a few of other studies did not support the existence of the inverse relationship between
94 birth weight and CKD (Fagerudd et al., 2006; Haysom et al., 2007), and sometimes
95 even reported contradictory findings (Vasarhelyi et al., 2000). For example, no early
96 glomerular and tubular damage was observed in young men with low birth weight
97 compared with those with normal birth weight (Vasarhelyi et al., 2000).

98 The inconsistent observations regarding the relationship between birth weight and
99 CKD may be also partly due to uncontrolled/unknown confounders which are
100 commonly encountered in observational studies. Indeed, there are studies which
101 suggested that the impaired kidney function in adulthood may be a consequence of
102 high blood pressure (Vasarhelyi et al., 2000). Thus, it remains a concern when
103 interpreting the observed relationship between birth weight and CKD as a causal
104 association. A cohort longitudinal study may alleviate such concern and offer an
105 important insight into the causal interpretation. However, longitudinal studies require
106 large scale subjects and need very long-term follow-ups before CKD clinical
107 presentation. Traditionally, randomized controlled trials (RCT) studies are the gold
108 standard for inferring the causal effect of exposure on outcome. However, determining
109 the causal relationship between birth weight and CKD by RCT is infeasible. It seems
110 that the validation of the fetal origins hypothesis for CKD is extremely difficult in a
111 traditional manner.

112 In observational studies Mendelian randomization (MR) can help clarify the causal
113 relationship between an exposure of interest and an outcome, and provide an efficient
114 way for causal inference. Briefly, MR is a special instrumental variable method that
115 employs genetic variants (e.g. single nucleotide polymorphisms (SNPs)) as
116 instruments for an exposure (i.e. birth weight) and evaluates its causal effect on the
117 outcome (i.e. CKD). In the past ten years the great success of genome-wide
118 association studies (GWASs) makes it feasible to select suitable SNPs as effective
119 instruments for causal inference in MR. In fact, MR has recently become a
120 considerably popular approach of inferring causal relationship in observational
121 research ([Mokry et al., 2015](#); [Zeng et al., 2019a](#); [Zeng and Zhou, 2019b](#)). Indeed, birth
122 weight has been confirmed to be causally associated with many adult diseases (e.g.
123 cardiovascular disease ([Au Yeung et al., 2016](#); [Zanetti et al., 2018](#)) and type 2 diabetes
124 ([Wang et al., 2016](#))) through MR studies.

125 Motivated by those previous observations above, our main goal in this study was two
126 aspects. First, to illuminate whether there exists an association between birth weight
127 and CKD, we employed the systematic review and meta-analysis to provide a pooled
128 conclusion. The result showed that birth weight is inversely associated with CKD,
129 confirming the finding in other studies ([Lackland et al., 2000](#); [Fan et al., 2006](#); [Al
130 Salmi et al., 2008](#); [Oster et al., 2013](#); [Hirano et al., 2016](#)). Furthermore, to determine
131 whether this observed negative association is causal, we performed a largest and most
132 comprehensive MR analysis based on summary statistic data available from
133 large-scale GWASs with approximately 143,000 individuals for birth weight and
134 ~118,000 individuals for CKD.

135 **Materials and Methods**

136 **Systematic reviews and meta-analysis**

137 *Data sources and search strategies for previous studies*

138 Following the guideline of preferred reporting items for systematic reviews and
139 meta-analyses (PRISMA) (Moher et al., 2009), we performed a literature search
140 mainly on PubMed from January 1998 to April 2019 for articles on the relationship
141 between birth weight (and related factors including premature birth and fetal
142 development) and CKD. We made no restriction on study designs and considered both
143 cohort and population-based studies; but we limited articles in English. Originally, a
144 total of 2,072 articles (2,067 articles by searching and additional 5 articles by
145 references scanning) were obtained (Fig. S1). The following exclusion criteria for
146 articles filtering were employed: (1) the title and abstract did not contain any data on
147 birth weight and/or CKD; (2) insufficient results were available on birth weight and
148 CKD; (3) duplicated studies; (4) articles were a review, letter-to-editor, response or
149 commentary article; and (5) articles were about clinical drug trials for CKD; (6)
150 articles were about CKD in childhood. Based on those criteria, 20 studies were left in
151 our final meta-analysis.

152 *Data extraction and Statistical analysis in meta-analysis*

153 For each article that was incorporated into our meta-analysis, two investigators (XH
154 and PZ) independently carried out data extraction and quality assessment. From each
155 article we extracted the information about study setting and design, population and
156 sample size for case and control, effect size (e.g. odds ratio (OR), relative ratio (RR)
157 or hazard ratio (HR)) as well as covariates that were adjusted for in the original
158 analysis. The effect size heterogeneity among studies was tested by the Cochran's Q
159 statistic (Thompson and Sharp, 1999). We estimated the combined effect of birth
160 weight on CKD using a weighted meta-analysis method and evaluated the published
161 bias by the Egger method and funnel plot (Egger et al., 1997). We also performed a
162 leave-one-out (LOO) analysis to assess the influence of a single study.

163 **MR analysis**

164 *GWAS data sources for birth weight and CKD*

165 In our meta-analysis above we found that there exists a robust inverse association
166 between birth weight and CKD (see below for more details). To examine whether this
167 identified association is causal, we further performed a MR analysis based on large
168 scale GWAS genetic data of birth weight and CKD. To achieve this, we first yielded
169 the genetic data of birth weight from the Early Growth Genetics (EGG) consortium
170 (<http://egg-consortium.org>) (Horikoshi et al., 2016). In this study, birth weight was
171 measured as a continuous variable and an additive linear regression was adopted for
172 each SNP to detect its association with birth weight while controlling for available
173 covariates (e.g. gestational age). After quality control of SNP genotypes and
174 individuals, it contained summary association statistics (e.g. effect allele, marginal
175 effect size, standard error, p value and sample size) for 16,245,523 genotyped and
176 imputed SNPs on 143,677 individuals of European ancestry.

177 We next obtained the summary association statistics (e.g. marginal effect size,
178 standard error and p value) of CKD from the CKDGen consortium
179 (<http://ckdgen.imbi.uni-freiburg.de/>) (Pattaro et al., 2016). After quality control a total
180 of 118,147 European individuals (12,385 cases and 105,762 controls) and 2,191,883
181 SNPs were available for this CKD GWAS. Besides CKD, we also attempted to
182 explore the causal relationship between birth weight and other kidney-related
183 phenotypes which included eGFR based on serum creatinine (eGFR_{crea}) and cystatin
184 C (eGFR_{cys}) (Pattaro et al., 2016), annual decline of eGFR (eGFR change) and rapid
185 eGFR decline (Rapid Decline) (Gorski et al., 2015), urinary albumin-to-creatinine
186 ratio (UACR) and microalbuminuria (MA) (Teumer et al., 2016). The used GWAS
187 genetic data sets in our MR study are summarized in Table S1. Since participants had
188 given informed consent for data sharing as described in each of the original GWASs
189 and only summary association results were employed; therefore, ethical review was
190 not needed for our study.

191 *Estimation of causal effect of birth weight on CKD and sensitivity analyses*

192 We then employed MR approaches to determine the causal relationship between birth
193 weight and CKD. First, to ensure the validity of MR we carefully selected a set of
194 independent index associated ($p < 5.00E-8$) SNPs that can serve as valid instrumental

195 variables for birth weight. The summary information of those index SNPs for birth
196 weight and CKD are shown in [Table S2](#). Next, to quantitatively check whether the
197 selected instruments for birth weight are strong, we calculated the proportion of
198 phenotypic variance of birth weight explained by each instrument and computed the F
199 statistic as an empirical indicator of strong/weak instrument ([Noyce et al., 2017](#)). We
200 then performed the two-sample inverse-variance weighted (IVW) MR methods
201 ([Burgess et al., 2017](#)) to estimate the causal effect of birth weight on CKD in terms of
202 per standard deviation (SD) change in birth weight, where the SD of birth weight was
203 estimated to be about 488 grams ([Horikoshi et al., 2016](#)). Before the causal effect
204 estimation, to further ensure the validity of MR, we inspected the pleiotropic
205 associations by removing instruments that may be potentially related to CKD with an
206 adjusted p value less than 0.05 after Bonferroni correction. In our analysis no
207 instruments were excluded by this conservative manner. To examine the robustness of
208 results in the MR analysis, we carried out several sensitivity analyses: (1) weighted
209 median-based method ([Bowden et al., 2016](#)) and maximum likelihood method
210 ([Burgess et al., 2013](#)); (2) LOO analysis ([Noyce et al., 2017](#)) and MR-PRESSO test
211 ([Verbanck et al., 2018](#)) to validate instrumental outliers that can substantially impact
212 the causal effect estimate; (3) MR-Egger regression to detect directional pleiotropic
213 effects of instrument variables ([Burgess and Thompson, 2017](#)).

214 **Result**

215 **Combined effect of birth weight on CKD in systematic review and meta-analysis**

216 A total of 20 studies satisfied the inclusion criteria and were finally incorporated into
217 our systematic review and meta-analysis (Fig. S1). Most of the included studies were
218 carried out on European individuals. The extracted information of those studies is
219 shown in Table 1. All the studies reported the risk of CKD for low birth weight
220 compared with normal birth weight, and nine additionally reported the risk of CKD
221 for high birth weight compared with normal birth weight. Note that the definition of
222 low/high birth weight was slightly different across studies (see Table 1 for more
223 details). Among those, 16 studies showed that low birth weight can increase the risk
224 of CKD in later life. Additionally, five out of nine studies demonstrated that high birth
225 weight can also raise the risk of CKD. Those results suggested that there may exist a
226 U-shaped relationship between birth weight and CKD. We thus performed
227 meta-analysis for the association between low or high birth weight with CKD
228 separately (Fig. 1).

229 Owing to the presence of heterogeneous effect size of birth weight on CKD in those
230 studies (the p values of the Q statistic are less than 0.05 for both low and high birth
231 weight; Fig. 1), the results of the random-effects meta-analysis are displayed here.
232 Specifically, we found that the risk of CKD for adult individuals with low birth weight
233 is 76% (OR=1.76, 95% CI 1.37~2.26, $p=1.27E-5$) higher compared with those with
234 normal birth weight (Fig. 1A), implying that lower birth weight leads to more
235 vulnerable to CKD. This inverse relationship also holds in the sub-group
236 meta-analyses in terms of gender or the type of study design (Fig. S2-S3). However,
237 no significant association is observed between high birth weight and CKD (OR=1.05,
238 95% CI 0.81~1.37, $p=0.713$; Fig. 1B). These results are robust according to the LOO
239 analyses which show that no single study can substantially dominate the final
240 combined estimates (Table S3-S4). Additionally, the Egger test ($p=0.170$ for low birth
241 weight and $p=0.982$ for high birth weight), together with the funnel plot (Fig. S2),
242 demonstrates that the publication bias is less likely to influence the combined
243 estimates in our meta-analysis. In summary, based on the results of meta-analysis
244 above, we can conclude that an inverse association exists between birth weight and
245 CKD, but no evidence is present for the observed U-shaped relationship.

246 **Estimated causal effect of birth weight on CKD**

247 In our MR analysis, a total of 26 independent index SNPs served as instrument
248 variables for birth weight. They jointly explain a total of 0.91% of phenotypic
249 variance for birth weight. The F statistics of those instruments range from 27.6 to
250 175.6 (with an average of 49.26), indicating that the weak instrument bias does not
251 likely occur in our analysis. Little evidence of causal effect heterogeneity across
252 instruments is observed ($Q=23.08$ and $p=0.573$); therefore, we employed the
253 fixed-effects IVW MR method to estimate the causal effect and found that there exists
254 a negative but non-significant casual association between birth weight and CKD.
255 More specifically, the OR per one SD increase of birth weight on CKD is 0.91 (95%
256 CI 0.72~1.14, $p=0.396$), consistent with those produced by the weighted median
257 method (OR=0.86, 95% CI 0.62~1.18, $p=0.346$) and by the maximum likelihood
258 approach (OR=0.91, 95% CI 0.72~1.14, $p=0.414$). The similarly null causal
259 association was also observed if we employ other sets of instrumental variables for
260 birth weight ([Supplementary File](#)). In addition, we also did not discover a significant
261 casual association between birth weight and other kidney-related traits ([Fig. S5](#)).

262 We next examined whether there are potential instrument outliers and whether these
263 outliers have a substantial influence on the estimate of causal effect. To do so, we
264 created a scatter plot by drawing the effect sizes of SNPs of birth weight against those
265 SNPs of CKD for all the used instruments ([Fig. 2A](#)). It is shown that no instrumental
266 variables can be considered potential outliers. The result of MR-PRESSO also
267 displays that there do not exist instrument outliers at the significance level of 0.05.
268 Consistently, in terms of the result of the LOO analysis, no single instrument can have
269 a substantial influence on the estimation of causal effect ([Table S5](#)). The OR per one
270 SD increase of birth weight on CKD is estimated to be 0.55 (95% CI 0.26~1.17,
271 $p=0.120$) using the MR-Egger regression. Furthermore, the MR-Egger regression
272 removes the possibility of pleiotropic effects of instrument variables (the
273 intercept=0.015, 95% CI -0.007~0.037, $p=0.174$). The funnel plot also presents a
274 symmetric pattern around the causal effect point estimate ([Fig. 2B](#)), further indicating
275 the absence of horizontal pleiotropy. Overall, the MR results do not provide
276 statistically significant evidence that supports the direct causal association between
277 birth weight and CKD.

278 **Discussion**

279 To understand the relationship between birth weight and CKD, in the present study we
280 first performed a systematic review and meta-analysis. The results showed that
281 individuals with low birth weight would have a higher risk of CKD in adulthood
282 compared with those with normal weight, in line with previous observation ([Poulter et al., 1999](#);
283 [Al Salmi et al., 2007](#); [Khalsa et al., 2016](#)). The mechanism underlying this
284 inverse association between birth weight and CKD is very complicated ([Di Lullo et al., 2015](#);
285 [Webster et al., 2017](#)). Possible interpretations include the finding that low birth
286 weight can lead to the reduction of the number of kidney nephrons ([Luyckx et al., 2013](#)).
287 For example, it was observed that every 1 kg decrease of birth weight can
288 result in about 250,000 reduction in the number of unilateral nephrons ([Hoy et al., 2005](#)).
289 The relatively smaller number of nephrons for individuals with low birth
290 weight implies a higher susceptibility to kidney diseases in later life ([Brenner et al., 1988](#);
291 [Luyckx et al., 2017](#)). This finding was also supported by animal models which
292 showed that offspring had decreased kidney nephrons if being exposed to adverse
293 environmental conditions during pregnancy ([Bidani et al., 2013](#); [Horowitz et al., 2015](#)).
294 However, our results provided little evidence supporting the existence of
295 association between high birth weight and CKD although previous studies suggested
296 high birth weight can also elevate the risk of CKD.

297 To investigate whether this observed negative association between birth weight and
298 CKD in our meta-analysis is causal, we further carried out a two-sample MR analysis
299 based on summary statistics publicly available from large scale GWASs. Because MR
300 relies on the Mendel's second law which means that an allele of a gene can enter a
301 gamete independently of another gene. Therefore, MR is less likely affected by
302 confounding factors compared with observational studies ([Burgess et al., 2017](#)). In
303 our MR analysis, to improve the statistical power and meet the model assumptions we
304 used multiple instrument variables which were independent from each other and
305 strongly associated with birth weight. We also tried to avoid the pleiotropic effects of
306 instruments by removing index SNPs that may be potentially related with CKD.
307 Further sensitive analyses (e.g. Egger regression) also excluded the likelihood of
308 pleiotropy that can introduce bias into the causal effect estimation. However, the
309 results of MR did not offer statistically significant evidence supporting the direct

310 causal relationship between birth weight and CKD.

311 Several explanations exist in this observed association. Especially, after birth the
312 threat to the survival of the nephron still exists. Infants with low birth weight are often
313 accompanied by a decrease in the number of nephrons due to impaired renal function
314 development. The decrease in the number of nephrons may result in glomerular
315 hypertrophy and high filtration rate, which ultimately leads to secondary glomerular
316 sclerosis. As one of the important risk factors for CKD (Coca et al., 2012), acute
317 kidney injury occurs in 18-40% of very low birth weight infants (Koralkar et al.,
318 2011). Additionally, most of infants with very low birth weight receive at least one
319 nephrotoxic drug treatment before discharge, which can potentially affect kidney
320 function (Rhone et al., 2014). Infants with low birth weight or limited intrauterine
321 growth often experience accelerated "catch-up" growth, which is also associated with
322 CKD (Fagerberg et al., 2004).

323 Nevertheless, we note that the estimated causal effects between birth weight and CKD
324 were consistent in the direction and magnitude through multiple MR methods (e.g.
325 IVW, weighted median method and maximum likelihood estimation). There are
326 several explanations for the failure of detecting a causal association between birth
327 weight and CKD given the observation that low birth weight is robustly related to the
328 increased risk of CKD in our meta-analysis. First, this inverse relationship in
329 observational studies may be driven by shared genetic components between birth
330 weight and CKD. To check this, we applied the linkage disequilibrium score
331 regression (LDSC) (Bulik-Sullivan et al., 2015) to quantify the genetic covariance
332 between birth weight and CKD. LDSC is a novel statistical genetic method for
333 quantifying genetic correlation for two traits based on the genome-wide pleiotropy
334 (note that our MR analysis has removed the influence of pleiotropic effects). With
335 LDSC, we found a pronounced but nonsignificant genetic correlation between birth
336 weight and CKD ($R_g = -0.234$, $se = 0.081$, $p = 0.771$; see Table S6 for more information),
337 suggesting the common polygenic risk shared by low birth weight and CKD. More
338 specifically, this means that some SNPs that are associated with low birth weight also
339 related to the risk of CKD. Second, the failure of detecting non-zero causal effect of
340 birth weight on CKD may be partly due to a lack of adequate statistical power. To
341 examine this, we performed the statistical power calculation to discover an OR of 0.80

342 or 0.90 in the risk of CKD per unit change of birth weight following the approach
343 shown in (Brion et al., 2013). Note that, these assumed ORs approximately equal to
344 the estimated effect size of birth weight on CKD in our study. The results imply that
345 we have a small to moderate power to detect the causal association between birth
346 weight and CKD due to the small number of CKD cases (Fig. 3). For example, with
347 the current sample size of CKD in our study (i.e. assume the sample size of adult
348 CKD is 117,000 and the proportion of cases is 10.6%), the estimated statistical power
349 is 17% or 25% to detect an OR of 0.80 or 0.90, respectively. Third, we cannot rule out
350 the possibility that there exist some unknown pathways which mediate the influence
351 of birth weight on CKD. Note that the existence of mediation effect (or indirect effect)
352 of birth weight does not violate the model assumptions of MR. For example, it is
353 well-established that low birth weight can increase the risk of coronary heart disease,
354 diabetes and hypertension; the latter two are the major causes of CKD (Wingen et al.,
355 1997; Jafar et al., 2003; Ardissino et al., 2004; Targher et al., 2008; Jha et al., 2013),
356 implying that birth weight can have an impact on CKD by the metabolic or
357 cardiovascular pathway.

358 **Limitation**

359 Finally, some limitations of this study should be considered. First, both birth weight
360 (and all corresponding antecedents and early risk factors) and CKD are heterogeneous
361 phenotypes; for example, among adult CKDs, polycystic kidney disease is currently
362 known as a hereditary kidney disorder and is one of the most common autosomal
363 dominant diseases (Gabow, 1993; Chapman et al., 2015). Diabetic nephropathy is
364 caused by lifestyle and genetic factors and Hypertensive kidney disease is more
365 caused by environmental factors (Go et al., 2004; Vivante and Hildebrandt, 2016).
366 Therefore, when combining these heterogeneous CKDs together in analysis, a large
367 degree of deviation may be introduced in our analysis. Second, as mentioned above,
368 we have only a limited statistical power in our MR analysis due to the small sample
369 size of cases in the CKD GWAS. Third, like many previous MR studies we
370 hypothesized that there is a linear relationship between birth weight and CKD in our
371 analysis. Linearity may be unreasonable in practice since previous epidemiological
372 studies have found that high birth weight also increases the risk of CKD, implying a
373 U-type relationship between birth weight and CKD. Therefore, we cannot completely
374 remove the nonlinear influence of birth weight on CKD. Fourth, our MR relies on

375 summary statistics rather than individual-level data sets, thus we cannot analyze the
376 relationship between very low/high birth weight and CKD due to lack of relevant data
377 information, and we are also unable to conduct stratified analyses (e.g. in terms of
378 gender; see [Table 1](#)) in our MR study.

379 In conclusion, our study identifies an inverse association between birth weight and
380 CKD in observational studies, while it is not supportive of the causal role of birth
381 weight on the risk of CKD based on our MR analysis.

382 **Acknowledgements**

383 We thank all the EGG and CKDGen consortium studies for making the summary data
384 publicly available and we are grateful of all the investigators and participants
385 contributed to those studies. The data analyses in the present study were supported by
386 the high-performance computing at Xuzhou Medical University.

387 **Author Contributions**

388 PZ and SH conceived the idea for the study; PZ and XY obtained the data; PZ and XY
389 cleared up the datasets; PZ, XY and ZY mainly performed the data analyses; HC, YG
390 and JY helped clear and analyze the data; PZ, XY, ZY and FG interpreted the results
391 of the data analyses; PZ and XY wrote the manuscript, and other authors approved the
392 manuscript and provided relevant suggestions.

393 **Disclosure**

394 The authors declare that the research was conducted in the absence of any commercial
395 or financial relationships that could be construed as a potential conflict of interest.

396 **Funding**

397 This study was supported by the National Natural Science Foundation of Jiangsu
398 (BK20181472), Youth Foundation of Humanity and Social Science funded by
399 Ministry of Education of China (18YJC910002), the China Postdoctoral Science
400 Foundation (2018M630607 and 2019T120465), Jiangsu QingLan Research Project for
401 Outstanding Young Teachers and Six Talent Peaks Project of Jiangsu Province of
402 China (WSN-087), the Postdoctoral Science Foundation of Xuzhou Medical
403 University, the National Natural Science Foundation of China (81402765), the
404 Statistical Science Research Project from National Bureau of Statistics of China
405 (2014LY112), the Postgraduate Research & Practice Innovation Program of Jiangsu
406 Province (KYCX19_2250), and the Priority Academic Program Development of
407 Jiangsu Higher Education Institutions (PAPD) for Xuzhou Medical University.

408 **Supplementary material**

409 Supplementary File.

410 Reference

- 411 1. Al Salmi, I., Hoy, W., Kondalsamy-Chennakesavan, S., Wang, Z., Gobe, G., Healy,
412 H., et al. (2007). Adult chronic kidney disease patients have lower birth weight
413 than the general Australian population. *Early Human Development* 83(Supp. 1),
414 S109-S109.
- 415 2. Al Salmi, I., Hoy, W.E., Kondalsamy-Chennakes, S., Wang, Z., Healy, H., and
416 Shaw, J.E. (2008). Birth Weight and Stages of CKD: A Case-Control Study in an
417 Australian Population. *American Journal of Kidney Diseases* 52(6), 1070-1078.
418 doi: 10.1053/j.ajkd.2008.04.028.
- 419 3. Ardissino, G., Testa, S., Dacco, V., Viganò, S., Taioli, E., Claris-Appiani, A., et al.
420 (2004). Proteinuria as a predictor of disease progression in children with
421 hypodysplastic nephropathy - Data from the ItalKid Project. *Pediatric*
422 *Nephrology* 19(2), 172-177. doi: 10.1007/s00467-003-1268-0.
- 423 4. Au Yeung, S.L., Lin, S.L., Li, A.M., and Schooling, C.M. (2016). Birth weight
424 and risk of ischemic heart disease: A Mendelian randomization study. *Scientific*
425 *Reports* 6, 38420. doi: 10.1038/srep38420.
- 426 5. Barker, D.J. (1990). The fetal and infant origins of adult disease. *British Medical*
427 *Journal* 301(6761), 1111-1111. doi: 10.1136/bmj.301.6761.1111.
- 428 6. Barnett, C., Nnoli, O., Abdulmahdi, W., Nesi, L., Shen, M., Zullo, J.A., et al.
429 (2017). Low birth weight is associated with impaired murine kidney development
430 and function. *Pediatr Res* 82(2), 340-348. doi: 10.1038/pr.2017.53.
- 431 7. Berglund, D., MacDonald, D., Jackson, S., Spong, R., Issa, N., Kukla, A., et al.
432 (2014). Low birthweight and risk of albuminuria in living kidney donors. *Clinical*
433 *Transplantation* 28(3), 361-367. doi: 10.1111/ctr.12321.
- 434 8. Bidani, A.K., Polichnowski, A.J., Loutzenhiser, R., and Griffin, K.A. (2013).
435 Renal microvascular dysfunction, hypertension and CKD progression. *Current*
436 *Opinion in Nephrology and Hypertension* 22(1), 1-9. doi:
437 10.1097/MNH.0b013e32835b36c1.
- 438 9. Bowden, J., Smith, G.D., Haycock, P.C., and Burgess, S. (2016). Consistent
439 Estimation in Mendelian Randomization with Some Invalid Instruments Using a
440 Weighted Median Estimator. *Genetic Epidemiology* 40(4), 304-314. doi:
441 10.1002/gepi.21965.
- 442 10. Brenner, B.M., Garcia, D.L., and Anderson, S. (1988). Glomeruli and blood
443 pressure. Less of one, more the other? *American journal of hypertension* 1(4 Pt 1),
444 335-347. doi: 10.1093/ajh/1.4.335.
- 445 11. Brion, M.-J.A., Shakhbazov, K., and Visscher, P.M. (2013). Calculating statistical
446 power in Mendelian randomization studies. *International Journal of*
447 *Epidemiology* 42(5), 1497-1501. doi: 10.1093/ije/dyt179.
- 448 12. Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Patterson,
449 N., et al. (2015). LD Score regression distinguishes confounding from
450 polygenicity in genome-wide association studies. *Nature Genetics* 47(3), 291. doi:
451 10.1038/ng.3211.
- 452 13. Burgess, S., Butterworth, A., and Thompson, S.G. (2013). Mendelian
453 Randomization Analysis With Multiple Genetic Variants Using Summarized Data.
454 *Genetic Epidemiology* 37(7), 658-665. doi: 10.1002/gepi.21758.
- 455 14. Burgess, S., Small, D.S., and Thompson, S.G. (2017). A review of instrumental
456 variable estimators for Mendelian randomization. *Statistical Methods in Medical*
457 *Research* 26(5), 2333-2355. doi: 10.1177/0962280215597579.
- 458 15. Burgess, S., and Thompson, S.G. (2017). Interpreting findings from Mendelian

- 459 randomization using the MR-Egger method. *European Journal of Epidemiology*
460 32(5), 377-389. doi: 10.1007/s10654-017-0255-x.
- 461 16. Chambers, J.C., Zhang, W., Lord, G.M., Van Der Harst, P., Lawlor, D.A., Sehmi,
462 J.S., et al. (2010). Genetic loci influencing kidney function and chronic kidney
463 disease. *Nature genetics* 42(5), 373. doi: 10.1038/ng.566.
- 464 17. Chapman, A.B., Devuyst, O., Eckardt, K.-U., Gansevoort, R.T., Harris, T., Horie,
465 S., et al. (2015). Autosomal-dominant polycystic kidney disease (ADPKD):
466 executive summary from a Kidney Disease: Improving Global Outcomes
467 (KDIGO) Controversies Conference. *Kidney international* 88(1), 17-27. doi:
468 10.1038/ki.2015.59.
- 469 18. Coca, S.G., Singanamala, S., and Parikh, C.R. (2012). Chronic kidney disease
470 after acute kidney injury: a systematic review and meta-analysis. *Kidney*
471 *international* 81(5), 442-448. doi: 10.1038/ki.2011.379.
- 472 19. Das, S.K., Mannan, M., Faruque, A.S.G., Ahmed, T., McIntyre, H.D., and Al
473 Mamun, A. (2016). Effect of birth weight on adulthood renal function: A
474 bias-adjusted meta-analytic approach. *Nephrology* 21(7), 547-565. doi:
475 10.1111/nep.12732.
- 476 20. Di Lullo, L., House, A., Gorini, A., Santoboni, A., Russo, D., and Ronco, C.
477 (2015). Chronic kidney disease and cardiovascular complications. *Heart Failure*
478 *Reviews* 20(3), 259-272. doi: 10.1007/s10741-014-9460-9.
- 479 21. Dyck, R., Klomp, H., Tan, L., and Stang, M.R. (2003). An association of maternal
480 age and birth weight with end-stage renal disease in Saskatchewan - Sub-analysis
481 of registered Indians and those with diabetes. *American Journal of Nephrology*
482 23(6), 395-402. doi: 10.1159/000074066.
- 483 22. Egger, M., Davey Smith, G., Schneider, M., and Minder, C. (1997). Bias in
484 meta-analysis detected by a simple, graphical test. *Bmj* 315(7109), 629-634. doi:
485 10.1136/bmj.315.7109.629.
- 486 23. Eriksson, J.G., Salonen, M.K., Kajantie, E., and Osmond, C. (2018). Prenatal
487 Growth and CKD in Older Adults: Longitudinal Findings From the Helsinki Birth
488 Cohort Study, 1924-1944. *Am J Kidney Dis* 71(1), 20-26. doi:
489 10.1053/j.ajkd.2017.06.030.
- 490 24. Fagerberg, B., Bondjers, L., and Nilsson, P. (2004). Low birth weight in
491 combination with catch-up growth predicts the occurrence of the metabolic
492 syndrome in men at late middle age: the Atherosclerosis and Insulin Resistance
493 study. *J Intern Med* 256(3), 254-259. doi: 10.1111/j.1365-2796.2004.01361.x.
- 494 25. Fagerudd, J., Forsblom, C., Pettersson-Fernholm, K., Saraheimo, M., Wadén, J.,
495 Rönback, M., et al. (2006). Low birth weight does not increase the risk of
496 nephropathy in Finnish type 1 diabetic patients. *Nephrology Dialysis*
497 *Transplantation* 21(8), 2159-2165.
- 498 26. Fan, Z.J., Lackland, D.T., Lipsitz, S.R., and Nicholas, J.S. (2006). The
499 Association of Low Birthweight and Chronic Renal Failure among Medicaid
500 Young Adults with Diabetes and/or Hypertension. *Public Health Reports* 121(3),
501 239-244. doi: 10.1177/003335490612100304.
- 502 27. Gabow, P.A. (1993). Autosomal dominant polycystic kidney disease. *New*
503 *England Journal of Medicine* 329(5), 332-342. doi:
504 10.1056/NEJM199307293290508.
- 505 28. Go, A.S., Chertow, G.M., Fan, D., McCulloch, C.E., and Hsu, C.-y. (2004).
506 Chronic kidney disease and the risks of death, cardiovascular events, and
507 hospitalization. *New England Journal of Medicine* 351(13), 1296-1305. doi:
508 10.1056/NEJMoa041031.

- 509 29. Gorski, M., Tin, A., Garnaas, M., McMahon, G.M., Chu, A.Y., Tayo, B.O., et al.
510 (2015). Genome-wide association study of kidney function decline in individuals
511 of European descent. *Kidney International* 87(5), 1017-1029. doi:
512 10.1038/ki.2014.361.
- 513 30. Hallan, S., Euser, A.M., Irgens, L.M., Finken, M.J., Holmen, J., and Dekker, F.W.
514 (2008). Effect of intrauterine growth restriction on kidney function at young adult
515 age: the Nord Trondelag Health (HUNT 2) Study. *Am J Kidney Dis* 51(1), 10-20.
516 doi: 10.1053/j.ajkd.2007.09.013.
- 517 31. Haysom, L., Williams, R., Hodson, E., Roy, L.P., Lyle, D., and Craig, J.C. (2007).
518 Early chronic kidney disease in Aboriginal and non-Aboriginal Australian
519 children: remoteness, socioeconomic disadvantage or race? *Kidney International*
520 71(8), 787-794. doi: 10.1038/sj.ki.5002099.
- 521 32. Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O'Callaghan, C.A., Lasserson, D.S.,
522 et al. (2016). Global Prevalence of Chronic Kidney Disease - A Systematic
523 Review and Meta-Analysis. *Plos One* 11(7). doi: 10.1371/journal.pone.0158765.
- 524 33. Hirano, D., Ishikura, K., Uemura, O., Ito, S., Wada, N., Hattori, M., et al. (2016).
525 Association between low birth weight and childhood-onset chronic kidney
526 disease in Japan: a combined analysis of a nationwide survey for paediatric
527 chronic kidney disease and the National Vital Statistics Report. *Nephrol Dial*
528 *Transplant* 31(11), 1895-1900. doi: 10.1093/ndt/gfv425.
- 529 34. Horikoshi, M., Beaumont, R.N., Day, F.R., Warrington, N.M., Kooijman, M.N.,
530 Fernandez-Tajes, J., et al. (2016). Genome-wide associations for birth weight and
531 correlations with adult disease. *Nature* 538(7624), 248. doi: 10.1038/nature19806.
- 532 35. Horowitz, B., Miskulin, D., and Zager, P. (2015). Epidemiology of Hypertension
533 in CKD. *Advances in Chronic Kidney Disease* 22(2), 88-95. doi:
534 10.1053/j.ackd.2014.09.004.
- 535 36. Hoy, W.E., Hughson, M.D., Bertram, J.F., Douglas-Denton, R., and Amann, K.
536 (2005). Nephron number, hypertension, renal disease, and renal failure. *Journal*
537 *of the American Society of Nephrology* 16(9), 2557-2564. doi:
538 10.1681/asn.2005020172.
- 539 37. Iwagami, M., Mansfield, K.E., Hayes, J.F., Walters, K., Osborn, D.P.J., Smeeth,
540 L., et al. (2018). Severe mental illness and chronic kidney disease: a
541 cross-sectional study in the United Kingdom. *Clinical Epidemiology* 10. doi:
542 10.2147/clep.s154841.
- 543 38. Jafar, T.H., Stark, P.C., Schmid, C.H., Landa, M., Maschio, G., de Jong, P.E., et al.
544 (2003). Progression of chronic kidney disease: The role of blood pressure control,
545 proteinuria, and angiotensin-converting enzyme inhibition - A patient-level
546 meta-analysis. *Annals of Internal Medicine* 139(4), 244-252. doi:
547 10.7326/0003-4819-139-4-200308190-00006.
- 548 39. Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., et al. (2013).
549 Chronic kidney disease: global dimension and perspectives. *Lancet* 382(9888),
550 260-272. doi: 10.1016/s0140-6736(13)60687-x.
- 551 40. Khalsa, D.D.K., Beydoun, H.A., and Carmody, J.B. (2016). Prevalence of chronic
552 kidney disease risk factors among low birth weight adolescents. *Pediatric*
553 *Nephrology* 31(9), 1509-1516. doi: 10.1007/s00467-016-3384-7.
- 554 41. Koralkar, R., Ambalavanan, N., Levitan, E.B., McGwin, G., Goldstein, S., and
555 Askenazi, D. (2011). Acute kidney injury reduces survival in very low birth
556 weight infants. *Pediatric research* 69(4), 354. doi:
557 10.1203/PDR.0b013e31820b95ca.
- 558 42. Köttgen, A., Pattaro, C., Böger, C.A., Fuchsberger, C., Olden, M., Glazer, N.L., et

- 559 al. (2010). New loci associated with kidney function and chronic kidney disease.
560 *Nature genetics* 42(5), 376. doi: 10.1038/ng.568.
- 561 43. Lackland, D.T., Bendall, H.E., Osmond, C., Egan, B.M., and Barker, D.J. (2000).
562 Low birth weights contribute to high rates of early-onset chronic renal failure in
563 the Southeastern United States. *Arch Intern Med* 160(10), 1472-1476.
- 564 44. Lackland, D.T., Egan, B.M., Fan, Z.J., and Syddall, H.E. (2001). Low birth
565 weight contributes to the excess prevalence of end-stage renal disease in African
566 Americans. *J Clin Hypertens (Greenwich)* 3(1), 29-31. doi:
567 10.1111/j.1524-6175.2001.00828.x.
- 568 45. Levey, A.S., Becker, C., and Inker, L.A. (2015). Glomerular Filtration Rate and
569 Albuminuria for Detection and Staging of Acute and Chronic Kidney Disease in
570 Adults A Systematic Review. *Jama-Journal of the American Medical Association*
571 313(8), 837-846. doi: 10.1001/jama.2015.0602.
- 572 46. Li, S., Chen, S.C., Shlipak, M., Bakris, G., McCullough, P.A., Sowers, J., et al.
573 (2008). Low birth weight is associated with chronic kidney disease only in men.
574 *Kidney Int* 73(5), 637-642. doi: 10.1038/sj.ki.5002747.
- 575 47. Luyckx, V.A., Bertram, J.F., Brenner, B.M., Fall, C., Hoy, W.E., Ozanne, S.E., et
576 al. (2013). Effect of fetal and child health on kidney development and long-term
577 risk of hypertension and kidney disease. *Lancet* 382(9888), 273-283. doi:
578 10.1016/s0140-6736(13)60311-6.
- 579 48. Luyckx, V.A., and Brenner, B.M. (2015). Birth weight, malnutrition and
580 kidney-associated outcomes-a global concern. *Nature Reviews Nephrology* 11(3),
581 135-149. doi: 10.1038/nrneph.2014.251.
- 582 49. Luyckx, V.A., Perico, N., Somaschini, M., Manfellotto, D., Valensise, H., Cetin, I.,
583 et al. (2017). A developmental approach to the prevention of hypertension and
584 kidney disease: a report from the Low Birth Weight and Nephron Number
585 Working Group. *Lancet* 390(10092), 424-428. doi:
586 10.1016/s0140-6736(17)30576-7.
- 587 50. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred reporting
588 items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*
589 (*Clinical Research Ed.*) 339. doi: 10.1136/bmj.b2535.
- 590 51. Mokry, L.E., Ross, S., Ahmad, O.S., Forgetta, V., Smith, G.D., Leong, A., et al.
591 (2015). Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization
592 Study. *Plos Medicine* 12(8). doi: 10.1371/journal.pmed.1001866.
- 593 52. Nelson, R.G., Morgenstern, H., and Bennett, P.H. (1998). Birth weight and renal
594 disease in Pima Indians with type 2 diabetes mellitus. *Am J Epidemiol* 148(7),
595 650-656. doi: 10.1093/aje/148.7.650.
- 596 53. Noyce, A.J., Kia, D.A., Hemani, G., Nicolas, A., Price, T.R., De Pablo-Fernandez,
597 E., et al. (2017). Estimating the causal influence of body mass index on risk of
598 Parkinson disease: A Mendelian randomisation study. *Plos Medicine* 14(6). doi:
599 10.1371/journal.pmed.1002314.
- 600 54. Organization, W.H. (2018). "Mortality and global health estimates: Causes of
601 death; Projections for 2015–2030; Projection of death rates". Geneva: WHO).
- 602 55. Oster, R.T., Luyckx, V.A., and Toth, E.L. (2013). Birth weight predicts both
603 proteinuria and overweight/obesity in a rural population of Aboriginal and
604 non-Aboriginal Canadians. *Journal of Developmental Origins of Health and*
605 *Disease* 4(2), 139-145. doi: 10.1017/s2040174412000724.
- 606 56. Painter, R.C., Roseboom, T.J., Van Montfrans, G.A., Bossuyt, P.M., Krediet, R.T.,
607 Osmond, C., et al. (2005). Microalbuminuria in adults after prenatal exposure to
608 the Dutch famine. *Journal of the American Society of Nephrology* 16(1), 189-194.

- 609 doi: 10.1681/ASN.2004060474.
- 610 57. Pattaro, C., Teumer, A., Gorski, M., Chu, A.Y., Li, M., Mijatovic, V., et al. (2016).
611 Genetic associations at 53 loci highlight cell types and biological pathways
612 relevant for kidney function. *Nature Communications* 7. doi:
613 10.1038/ncomms10023.
- 614 58. Poulter, N.R., Chang, C.L., MacGregor, A.J., Snieder, H., and Spector, T.D.
615 (1999). Association between birthweight and adult blood pressure in twins:
616 historical cohort study. *British Medical Journal* 319(7221), 1330-1333. doi:
617 10.1136/bmj.319.7221.1330.
- 618 59. Rhone, E.T., Carmody, J.B., Swanson, J.R., and Charlton, J.R. (2014).
619 Nephrotoxic medication exposure in very low birth weight infants. *The Journal of*
620 *Maternal-Fetal & Neonatal Medicine* 27(14), 1485-1490. doi:
621 10.3109/14767058.2013.860522.
- 622 60. Ruggajo, P., Svarstad, E., Leh, S., Marti, H.P., Reisaether, A.V., and Vikse, B.E.
623 (2016). Low Birth Weight and Risk of Progression to End Stage Renal Disease in
624 IgA Nephropathy--A Retrospective Registry-Based Cohort Study. *PLoS One*
625 11(4), e0153819. doi: 10.1371/journal.pone.0153819.
- 626 61. Targher, G., Chonchol, M., Bertolini, L., Rodella, S., Zenari, L., Lippi, G., et al.
627 (2008). Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty
628 Liver Disease. *Journal of the American Society of Nephrology* 19(8), 1564-1570.
629 doi: 10.1681/asn.2007101155.
- 630 62. Teumer, A., Tin, A., Sorice, R., Gorski, M., Yeo, N.C., Chu, A.Y., et al. (2016).
631 Genome-wide Association Studies Identify Genetic Loci Associated With
632 Albuminuria in Diabetes. *Diabetes* 65(3), 803-817. doi: 10.2337/db15-1313.
- 633 63. Thompson, S.G., and Sharp, S.J. (1999). Explaining heterogeneity in
634 meta-analysis: A comparison of methods. *Statistics in Medicine* 18(20),
635 2693-2708. doi:
636 10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v.
- 637 64. Vasarhelyi, B., Dobos, M., Reusz, G.S., Szabo, A., and Tulassay, T. (2000).
638 Normal kidney function and elevated natriuresis in young men born with low
639 birth weight. *Pediatr Nephrol* 15(1-2), 96-100.
- 640 65. Verbanck, M., Chen, C.-Y., Neale, B., and Do, R. (2018). Detection of
641 widespread horizontal pleiotropy in causal relationships inferred from Mendelian
642 randomization between complex traits and diseases. *Nature Genetics* 50(5), 693.
643 doi: 10.1038/s41588-018-0099-7.
- 644 66. Vikse, B.E., Irgens, L.M., Leivestad, T., Hallan, S., and Iversen, B.M. (2008).
645 Low birth weight increases risk for end-stage renal disease. *J Am Soc Nephrol*
646 19(1), 151-157. doi: 10.1681/asn.2007020252.
- 647 67. Vivante, A., and Hildebrandt, F. (2016). Exploring the genetic basis of early-onset
648 chronic kidney disease. *Nature Reviews Nephrology* 12(3), 133. doi:
649 10.1038/nrneph.2015.205.
- 650 68. Wang, J., Wang, B., Liang, M., Wang, G., Li, J., Zhang, Y., et al. (2018).
651 Independent and combined effect of bilirubin and smoking on the progression of
652 chronic kidney disease. *Clinical Epidemiology* 10, 121-132. doi:
653 10.2147/clep.s150687.
- 654 69. Wang, T., Huang, T., Li, Y., Zheng, Y., Manson, J.E., Hu, F.B., et al. (2016). Low
655 birthweight and risk of type 2 diabetes: a Mendelian randomisation study.
656 *Diabetologia* 59(9), 1920-1927. doi: 10.1007/s00125-016-4019-z.
- 657 70. Webster, A.C., Nagler, E.V., Morton, R.L., and Masson, P. (2017). Chronic kidney
658 disease. *Lancet* 389(10075), 1238-1252. doi: 10.1016/s0140-6736(16)32064-5.

- 659 71. White, S.L., Perkovic, V., Cass, A., Chang, C.L., Poulter, N.R., Spector, T., et al.
660 (2009). Is Low Birth Weight an Antecedent of CKD in Later Life? A Systematic
661 Review of Observational Studies. *American Journal of Kidney Diseases* 54(2),
662 248-261. doi: 10.1053/j.ajkd.2008.12.042.
- 663 72. Wingen, A.M., FabianBach, C., Schaefer, F., and Mehls, O. (1997). Randomised
664 multicentre study of a low-protein diet on the progression of chronic renal failure
665 in children. *Lancet* 349(9059), 1117-1123. doi: 10.1016/s0140-6736(96)09260-4.
- 666 73. Yudkin, J.S., Martyn, C.N., Phillips, D.I.W., and Gale, C.R. (2001). Associations
667 of micro-albuminuria with intra-uterine growth retardation. *Nephron* 89(3),
668 309-314. doi: 10.1159/000046091.
- 669 74. Zanetti, D., Tikkanen, E., Gustafsson, S., Priest, J.R., Burgess, S., and Ingelsson,
670 E. (2018). Birthweight, Type 2 Diabetes Mellitus, and Cardiovascular Disease
671 Addressing the Barker Hypothesis With Mendelian Randomization.
672 *Circulation-Genomic and Precision Medicine* 11(6). doi:
673 10.1161/circgen.117.002054.
- 674 75. Zeng, P., Yu, X., and Xu, H. (2019). Association between premorbid body mass
675 index and amyotrophic lateral sclerosis: causal inference through genetic
676 approaches. *Frontiers in Neurology (in press)*. doi: 10.1101/526186.
- 677 76. Zeng, P., Yu, X., and Zhou, X. (2019). Birth weight is not causally associated with
678 adult asthma: results from instrumental variable analyses. *Scientific Reports* 9(1),
679 7647. doi: 10.1038/s41598-019-44114-5.
- 680 77. Zeng, P., and Zhou, X. (2019). Causal Association between Birth Weight and
681 Adult Diseases: Evidence from a Mendelian Randomisation Analysis. *Frontiers*
682 *in Genetics* 10, 618. doi: 10.3389/fgene.2019.00618.
- 683 78. Zeng, P., and Zhou, X. (2019). Causal effects of blood lipids on amyotrophic
684 lateral sclerosis: a Mendelian randomization study. *Human molecular genetics*
685 28(4), 688-697. doi: 10.1093/hmg/ddy384.
- 686

687 **Table and Figure Legend**

688 **Table 1.** Summary information of 20 studies included in the meta-analysis for investigating the relationship between birth weight and chronic
 689 kidney disease

First author (year)	Country	Study design	N	Exposure Reference (g)	vs	OR (95% CI)	Covariates
Information for the relationship between low birth weight and CKD							
Nelson (1998) (Nelson et al., 1998)	USA	cohort study	308	<2,500	vs	2.30 (0.72~7.00)	age, sex, duration of DM, hemoglobin, A1c, mean arterial BP
Lackland (2000) (Lackland et al., 2000)	USA	case-control	3,690	<2,500	vs	1.40 (1.10~1.80)	unadjusted
Vasarhelyi (2000) (Vasarhelyi et al., 2000)	Hungary	cohort study	126	<2,500	vs	0.71 (0.20~2.80)	Sex
Lackland (2001) (Lackland et al., 2001)	USA	case-control	1,230	<2,500	vs	1.70 (1.00~2.80)	unadjusted
Yudkin (2001) (Yudkin et al., 2001)	UK	cohort study	818	3,000~3,999	vs	3.10 (0.90~11.30)	age, sex, BMI, SBP, region, fasting glucose
Dyck (2003) (Dyck et al., 2003)	Canada	case-control	878	ponderal index lower 3 rd vs other	in	1.62 (0.88~2.96)	unadjusted
Painter (2005) (Painter et al., 2005)	Netherlands	cohort study	724	<2,500	vs	3.22 (1.34~7.65)	age, sex, BMI, smoking, SES, SBP, IGT/NIDDM, cholesterol, ECG abnormalities
Fagerudd (2006) (Fagerudd et al., 2006)	Finland	cohort study	1,543	2,501~3,999	vs.	0.99 (0.61, 1.62)	gestational age
Fan (2006) (Fan et al., 2006)	USA	cohort study	7,505	exposure to famine mid-gestation non-exposed	vs	1.56 (1.02~2.39)	age, sex, ethnicity, DM, hypertension
Salmi (2007) (Al Salmi et al., 2007)	Australia	cohort study	4,502	<10th percentile	vs	2.54 (1.54~4.18)	unadjusted
Haysom (2007) (Haysom et al., 2007)	Australia	cohort study	1,382	50 to 90th percentile	vs	0.95 (0.10~2.12)	age, sex, ethnicity, SES
Salmi (2008) (Al Salmi et al., 2008)	Australia	cross-control	567	<2,500	vs	3.60 (1.70~7.60)	age, sex, diabetes, hypertension, glomerulonephritis, and Reno-vascular disease
Hallan (2008) (Hallan et al., 2008)	Norway	cohort study	7,457	2,500~3,999	vs	1.63 (0.76~3.50)	age, smoking, education, maternal factors
Li (2008) (Li et al., 2008)	USA	retrospective cohort	12,364	<3rd percentile	vs	1.25 (0.81~1.92)	age, race, education, insurance, region, DM, HTN, CVD, family history of kidney disease, HTN control
Vikse (2008) (Vikse et al., 2008)	Norway	retrospective cohort	2.2 million	<2,500	vs	2.00 (1.40~2.80)	sex, birth year, birth order, congenital malformation, multiple delivery, maternal factors (age, marital status, preeclampsia)
Oster (2013) (Oster et al., 2013)	Canada	cohort study	1,439	2,500~4,499	vs	2.36 (1.24~4.49)	age and sex
Berglund (2014) (Berglund et al., 2014)	USA	case-control	216	<2,500 vs ≥2,500	vs	0.70 (0.28~1.74)	age, sex, BMI, time from donation, SBP, DBP

Hirano (2016) (Hirano et al., 2016)	Japan	case-control	20,620,003	<2,500 vs ≥2,500		4.21 (3.37~5.26)	birth year
Ruggajo (2016) (Ruggajo et al., 2016)	Norway	retrospective cohort	471	<10th percentile vs >10th percentile		1.40 (0.69~2.70)	glomerular filtration
Eriksson (2018) (Eriksson et al., 2018)	Finland	cohort study	1,060	≤2,500 vs 3,000-3,499		1.32 (0.79~2.22)	unadjusted
Information for the relationship between high birth weight and CKD							
Nelson (1998) (Nelson et al., 1998)	USA	cohort study	308	≥4,500 vs 2,500~4,499		3.20 (0.75~13.40)	age, sex, duration of DM, hemoglobin, A1c, mean arterial BP
Lackland (2000) (Lackland et al., 2000)	USA	case-control	2,690	≥4,000 vs 3,000~3,499		1.10 (0.90~1.40)	unadjusted
Dyck (2003) (Dyck et al., 2003)	Canada	case-control	878	>4,000 vs 2,501~3,999		0.74 (0.44~1.20)	unadjusted
Fagerudd (2006) (Fagerudd et al., 2006)	Finland	cohort study	1,543	>90th percentile vs 50 to 90th percentile		1.12 (0.60~2.08)	gestational age
Fan (2006) (Fan et al., 2006)	USA	cohort study	7,505	≥4,000 vs 2,500~3,999		1.29 (0.79~2.09)	age, sex, ethnicity, DM, hypertension
Li (2008) (Li et al., 2008)	USA	retrospective cohort	12,364	≥4,000 vs 3,000~3,999		1.41 (1.06~1.88)	age, race, education, insurance, region, DM, HTN, CVD, family history of kidney disease, HTN control
Vikse (2008) (Vikse et al., 2008)	Norway	retrospective cohort	2.2M	≥4,000 vs 2,501~4,499		3.20 (0.75~13.40)	sex, birth year, birth order, congenital malformation, multiple delivery, maternal factors (age, marital status, preeclampsia)
Oster (2013) (Oster et al., 2013)	Canada	cohort study	1,439	≥4,000 vs ≥2,500		0.56 (0.23~1.38)	age and sex
Eriksson (2018) (Eriksson et al., 2018)	Finland	cohort study	20,431	≥4,000 vs 3,000-3,499		0.59 (0.39~1.00)	unadjusted
Information for the relationship between low birth weight and CKD for male							
Lackland (2000) (Lackland et al., 2000)	USA	case-control	2,676	<2,500 vs 3,000~3,499		1.20 (0.90~1.60)	unadjusted
Dyck (2003) (Dyck et al., 2003)	Canada	case-control	183	<2,500 vs 2,501~3,999		1.12 (0.50~2.52)	unadjusted
Salmi (2007) (Al Salmi et al., 2007)	Australia	cohort study	NA	<2,500 vs ≥2,500		3.40 (2.11~5.36)	unadjusted
Hallan (2008) (Hallan et al., 2008)	Norway	cohort study	3,534	<2,450 vs 2,870-4,190		2.68 (1.58~4.51)	age, smoking, education, maternal factors
Li (2008) (Li et al., 2008)	USA	retrospective cohort	2,920	<2,500 vs 3,000~3,999		1.65 (0.90~1.25)	age, race, education, insurance, region, DM, HTN, CVD, family history of kidney disease, HTN control
Vikse (2008) (Vikse et al., 2008)	Norway	retrospective cohort	1,120,789	<2,500 vs 2,501~4,499		1.50 (0.89~2.40)	sex, birth year, birth order, congenital malformation, multiple delivery, maternal factors (age, marital status, preeclampsia)
Ruggajo (2016) (Ruggajo et al., 2016)	Norway	retrospective cohort	322	<10th percentile vs >10th percentile		1.10 (0.52~2.40)	glomerular filtration
Eriksson (2018) (Eriksson et al., 2018)	Finland	cohort study	572	≤2,500 vs 3,000-3,499		1.00 (0.49~1.99)	unadjusted
Information for the relationship between low birth weight and CKD for female							
Lackland (2000) (Lackland et al., 2000)	USA	cross-control	1,014	<2,500 vs 3,000~3,499		1.90 (1.20~3.00)	unadjusted
Dyck (2003) (Dyck et al., 2003)	Canada	cross-control	130	<2,500 vs 2,501~3,999		2.70 (1.05~6.95)	unadjusted

Salmi (2007) (Al Salmi et al., 2007)	Australia	cohort study	NA	<2,500 vs ≥2,500	2.04 (1.45~2.88)	unadjusted
Hallan (2008) (Hallan et al., 2008)	Norway	cohort study	3,923	<2,450 vs 2,870-4,190	1.01 (0.54~1.90)	age, smoking, education, maternal factors
Li (2008) (Li et al., 2008)	USA	retrospective cohort	9,444	<2,500 vs 3,000~3,999	1.07 (0.81~1.92)	age, race, education, insurance, region, DM, HTN, CVD, family history of kidney disease, HTN control
Vikse (2008) (Vikse et al., 2008)	Norway	retrospective cohort	1,061,909	<10th percentile vs 10 to 90th percentile	2.80 (1.80~4.40)	Sex, birth year, birth order, congenital malformation, multiple delivery, maternal factors (age, marital status, preeclampsia)
Ruggajo (2016) (Ruggajo et al., 2016)	Norway	retrospective cohort	139	<10th percentile vs >10th percentile	1.40 (0.32~6.40)	glomerular filtration
Eriksson (2018) (Eriksson et al., 2018)	Finland	cohort study	488	≤2,500 vs 3,000-3,499	1.99 (1.00~4.30)	unadjusted



690

Note: BMI: body mass index; DM: diabetes mellitus; SBP: systolic blood pressure; HTN: hypertension; CVD: cerebrovascular disease; PSGN: post streptococcal glomerulonephritis.


691 **Fig. 1.** Combined effect of birth weight on CKD in the meta-analysis based on
692 observational studies. **(A)** Combined effect for individuals with low birth weight
693 compared with those with normal birth weight based on twenty studies; **(B)** Combined
694 effect for individuals with high birth weight compared with those with normal birth
695 weight based on nine studies.

696 **Fig. 2. (A)** Relationship between the SNP effect size estimates of birth weight (x-axis)
697 and the corresponding effect size estimates of CKD (y-axis). In the plot, the 95% CIs
698 for the effect sizes of instruments on birth weight are shown as horizontal lines, while
699 the 95% CIs for the effect sizes of instruments on CKD are shown as vertical lines.
700 The line in red represents the estimated causal effect of birth weight on CKD obtained
701 using the IVW method while the blue line represents the estimated causal effect
702 produced by the MR-Egger regression. **(B)** Funnel plot for single causal effect
703 estimate of birth weight on CKD; the horizontal dot line denotes the estimated causal
704 effect with IVW.

705 **Fig. 3.** Statistical power estimated with the analytic method shown in (Brion et al.,
706 2013). In the estimation, the total phenotypic variance explained by instrumental
707 variables was set to be 0.91%, the significance level α was set to be 0.05, the
708 proportion of CKD cases was set to be from 0.1 to 0.5. Two situations of sample size
709 (i.e. 117,000 and 200,000) were considered. For each situation, the OR was assumed
710 to be 0.80 or 0.90, respectively.


A**B**

Statistical Power



Proportion of CKD cases

- $n=200,000$ and $OR=0.8$
- $n=117,000$ and $OR=0.8$
- $n=200,000$ and $OR=0.9$
- $n=117,000$ and $OR=0.9$

A**B**